EXACT Therapeutics and Cordance Medical announced a strategic partnership aimed at combining their breakthrough technologies to revolutionize drug delivery in the treatment of brain diseases. EXACT Therapeutics ' ACT® platform utilizes a unique approach to ultrasound-mediated, targeted drug enhancement. Their proprietary formulation, PS101, consists of highly engineered microbubble-microdroplet clusters that can be co-administered intravenously with a therapeutic agent.

The ACT® formulation is activated by ultrasound, enabling precise targeting of therapeutic enhancement to the desired location. Cordance Medical's NeuroAccessTM platform is designed to provide personalized, targeted opening of the BBB in a non-invasive, painless procedure designed to take 30 minutes or less. This technology allows the procedure to be performed in space-constrained environments such as community outpatient clinics and infusion treatment centers, making it more accessible to patients worldwide.

This strategic partnership will combine EXACT Therapeutics' ACT® technology and Cordance Medical's NeuroAccessTM platform, with the aim of delivering more effective drug therapy across the BBB. By integrating the two technologies, patients suffering from various brain diseases, including brain tumors and neurodegenerative disorders, will have access to cutting-edge, targeted treatment options in upcoming clinical trials.